Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208421
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Penack, Olaf | - |
dc.contributor.author | Peczynski, Christophe | - |
dc.contributor.author | Koenecke, Christian | - |
dc.contributor.author | Polge, Emmanuelle | - |
dc.contributor.author | Sanderson, Robin | - |
dc.contributor.author | Yakoub Agha, Ibrahim | - |
dc.contributor.author | Fegueux, Nathalie | - |
dc.contributor.author | Daskalakis, Michael | - |
dc.contributor.author | Collin, Matthew | - |
dc.contributor.author | Dreger, Peter | - |
dc.contributor.author | Kröger, Nicolaus | - |
dc.contributor.author | Schanz, Urs | - |
dc.contributor.author | Bloor, Adrian | - |
dc.contributor.author | Ganser, Arnold | - |
dc.contributor.author | Besley, Caroline | - |
dc.contributor.author | Wulf, Gerald G. | - |
dc.contributor.author | Novak, Urban | - |
dc.contributor.author | Moiseev, Ivan | - |
dc.contributor.author | Schoemans, Hélène | - |
dc.contributor.author | Basak, Grzegorz W. | - |
dc.contributor.author | Chabannon, Christian | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Glass, Bertram | - |
dc.contributor.author | Peric, Zinaida | - |
dc.date.accessioned | 2024-03-05T12:07:38Z | - |
dc.date.available | 2024-03-05T12:07:38Z | - |
dc.date.issued | 2023-09-27 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/208421 | - |
dc.description.abstract | We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1252811 | - |
dc.relation.ispartof | Frontiers in Immunology, 2023, vol. 14 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2023.1252811 | - |
dc.rights | cc by (c) Penack, Olaf et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Receptors cel·lulars | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Cell receptors | - |
dc.title | Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-10-31T09:54:15Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37828980 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-1252811.pdf | 571.52 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License